SPOTLIGHT -
Zanzalintinib shows early promise in advanced renal cell carcinoma
The novel TKI zanzalintinib demonstrated early efficacy signals with manageable toxicity in patients with advanced clear-cell renal cell carcinoma.
ctDNA emerging as biomarker to guide treatment decisions in renal cell carcinoma
Circulating tumor DNA is showing promise as a tool to guide decisions on treatment intensification and de-escalation in patients with renal cell carcinoma.
Researchers explore novel therapeutic approaches for rare kidney cancer subtype
Translocation renal cell carcinoma is a rare type of RCC that is typically characterized by gene fusions involving the MiT family of transcription factors including TFE3, TFEB, TFEC, and MiTF.
Radium-223 yields OS of approximately 18 months in mCRPC
“Our observations in this study show that radium-223 can be integrated into the treatment sequence for patients with (metastatic castration-resistant prostate cancer),” said Daniel Y. Song, MD.
Tumor mutation burden may predict outcomes from ADC in urothelial carcinoma
The ORR for patients was 47%. Of note, ORRs were higher in patients with specific alterations compared with wild type including ERBB2 (67% vs. 44%, respectively; P = .05) and TSC1 (68% vs. 25%; P = .04).
Neoadjuvant cabozantinib clinically active in renal cell carcinoma
Neoadjuvant cabozantinib was safe and induced a reduction in tumor size in all patients with locally advanced nonmetastatic clear cell renal cell carcinoma enrolled in a phase 2 trial.
Genomic analysis offers clinical insight into VHL-positive vs -negative ccRCC tumors
Patients with VHL-mutated ccRCC and VHL–wild type disease often had low positive PD-L1 expression.
QoL boost linked to higher lenvatinib dose in kidney cancer
The higher starting dose of lenvatinib was also associated with a prolonged time to deterioration.
